


BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

Date: 07.11.2025

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Ref: Scrip Code: 531752

Scrip ID: BIOGEN

Dear Sir / Madam,

Sub: Outcome of the Board Meeting of the board held on 7th November 2025.

Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Friday 07th November 2025 at the Registered Office of the Company and transacted the following major businesses:

1.) Considered and approved Un-audited financial results for the quarter and half year ended as on 30th September, 2025.

The board meeting commenced at 03:30 PM and concluded at 04:00 PM

Please take the above intimation in your records.

Thanking You.

FOR, BIOGEN PHARMACHEM INDUSTRIES LIMITED

Kelash Bunkar
Director

Registered Office Address: Shop No. 8, First Floor, Maker's – 1 Building, Jawahar Road, Rajkot-360001

E mail biogenpharmachem@gmail.com

Biogen Pharmachem Industries Limited

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com

Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2025

| Sl no. | Particulars | Quarter Ended | | | Six Months Ended | | (Rs. In lacs) |
|-----------|---|----------------|---------------|----------------|------------------|-----------------|------------------------|
| | | 30-Sep-25 | 30-Jun-25 | 30-Sep-24 | 30-Sep-25 | 30-Sep-24 | Year Ended 31 Mar 2025 |
| | (Refer Notes Below) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | INCOME | | | | | | |
| (a) | Revenue From Operation | - | - | - | - | - | - |
| (b) | Other Income | (10.49) | 154.28 | (65.05) | 143.79 | (74.15) | 83.84 |
| | Total Income from Operations (Net) | (10.49) | 154.28 | (65.05) | 143.79 | (74.15) | 83.84 |
| 2 | EXPENSES | | | | | | |
| (a) | Cost of material consumed | - | - | - | - | - | - |
| (b) | Changes in inventories of finished goods, work-in-progress, and stock-in-trade | - | - | - | - | - | - |
| (c) | Employee benefit expense | 5.13 | 6.33 | 1.03 | 11.46 | 2.41 | 16.79 |
| (d) | Finance Costs | - | - | - | - | - | - |
| (e) | Depreciation and amortization expense | - | - | - | - | - | - |
| (f) | Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately) | 33.54 | 13.47 | 33.65 | 47.01 | 39.00 | 96.32 |
| | Total Expenses | 38.67 | 19.80 | 34.68 | 58.47 | 41.41 | 113.11 |
| 3 | Profit / (Loss) from operations before exceptional items Tax (1-2) | (49.15) | 134.48 | (99.73) | 85.33 | (115.56) | (29.27) |
| 4 | Exceptional Items | - | - | - | - | - | - |
| 5 | Profit / (Loss) before Tax (3 ± 4) | (49.15) | 134.48 | (99.73) | 85.33 | (115.56) | (29.27) |
| 6 | Tax Expense | - | - | - | - | - | - |
| 7 | Net Profit / (Loss) after Tax (5 - 6) | (49.15) | 134.48 | (99.73) | 85.33 | (115.56) | (29.27) |
| 8 | Other Comprehensive Income (net of tax) | - | - | - | - | - | - |
| 9 | Total Comprehensive Income for the period (7 ± 8) | (49.15) | 134.48 | (99.73) | 85.33 | (115.56) | (29.27) |
| 10 | Paid-up equity share capital (Face Value of Rs.1/- each) | 9,026.03 | 9,026.03 | 6,526.03 | 9,026.03 | 6,526.03 | 6,526.03 |
| 11 | Other Equity | - | - | - | - | - | (903.26) |
| 12 | Earnings Per Share (of Rs. 1/- each) (not annualised): | | | | | | |
| | (a) Basic | (0.01) | 0.01 | (0.02) | 0.01 | (0.02) | (0.00) |
| | (b) Diluted | (0.01) | 0.01 | (0.02) | 0.01 | (0.02) | (0.00) |

Biogen Pharmachem Industries Limited

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com

(Rs. in Lakhs)

| Standalone Statement of Assets and Liabilities | | As at 30th September, 2025 | As at 31st March, 2025 |
|--|--|----------------------------|------------------------|
| Particulars | | Un-Audited | Audited |
| A | ASSETS | | |
| 1 | Non-current assets | | |
| | Property, plant and equipment | - | - |
| | Capital work-in-progress | - | - |
| | Other intangible assets | - | - |
| | Investments in subsidiaries, associates and joint ventures | - | - |
| | Financial assets | | |
| | Investments | 2,137.10 | 2,384.41 |
| | Loans | 7,549.39 | 6,551.73 |
| | Other financial assets | - | - |
| | Income Tax assets (net) | - | - |
| | Deferred tax assets (net) | - | - |
| | Other non-current assets | - | - |
| | Sub-total - Non-Current Assets | 9,686.49 | 8,936.14 |
| 2 | Current assets | | |
| | Inventories | - | - |
| | Financial assets | | |
| | Investments | - | - |
| | Trade receivables | - | - |
| | Cash and cash equivalents | 5.45 | 5.48 |
| | Bank balances other than Cash and Cash equivalents above | 31.05 | 196.15 |
| | Loans, Current | 8.51 | 7.33 |
| | Other financial assets | - | - |
| | Other current assets | 186.02 | 56.67 |
| | Assets classified as held for sale | - | - |
| | Sub-total - Current Assets | 231.04 | 265.63 |
| | TOTAL - ASSETS | 9,917.53 | 9,201.77 |
| B | EQUITY AND LIABILITIES | | |
| 1 | Equity | | |
| | Equity Share capital | 9,026.03 | 6,526.03 |
| | Other equity | 882.07 | 2,666.74 |
| | Sub-total - Shareholders' funds | 9,908.10 | 9,192.77 |
| 2 | LIABILITIES | | |
| | Non-current liabilities | | |
| | Financial liabilities | | |
| | Borrowings, non-Current | - | - |
| | Provisions | - | - |
| | Income tax liabilities (net) | - | - |
| | Other non-current liabilities | - | - |
| | Sub-total - Non-current liabilities | - | - |
| 3 | Current liabilities | | |
| | Financial liabilities | | |
| | Borrowings, Current | - | - |
| | Trade payables, Current | - | - |
| | Other financial liabilities | - | - |
| | Other current liabilities | 9.43 | 9.00 |
| | Provisions | - | - |
| | Current tax liabilities (net) | - | - |
| | Sub-total - Current liabilities | 9.43 | 9.00 |
| | TOTAL - EQUITY AND LIABILITIES | 9,917.53 | 9,201.77 |

Biogen Pharmachem Industries Limited

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 07, 2025.
- 2 The Statutory Auditors have carried out a limited review of the above financial result.
- 3 Company has only one segment and hence no separate segment result has been given.
- 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of the Board
For, Biogen Pharmachem Industries Limited

Place : Rajkot

Date : 07th November, 2025

Kelash Bunkar
Wholetime Director

Biogen Pharmachem Industries Limited

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2025

(Rs. in Lakhs, unless otherwise stated)

| Particulars | 30.09.2025 | 30.09.2024 |
|--|---------------|---------------|
| | Rupees | Rupees |
| A. CASH FLOW FROM OPERATING ACTIVITIES: | | |
| Profit before tax | 85.33 | 115.56 |
| Adjustment For : | | |
| Share of (profit)/loss from investment in partnership firm | - | - |
| Depreciation/amortization on continuing operation | - | - |
| Pre-operating Expense | - | - |
| Interest expenses | - | - |
| Operating profit before working capital changes | 85.33 | 115.56 |
| Movement in Working Capital : | | |
| Increase/(decrease) in Inventory | - | - |
| Increase/(decrease) in Trade receivables | - | - |
| Increase/(decrease) in Short Term Loan & Advances | 1.18 | - |
| Increase/(decrease) in Current Liabilities | 0.43 | 21.10 |
| Increase/(decrease) in Trade Payable | - | - |
| Increase/(decrease) in Other Current Assets | 129.35 | 150.04 |
| Direct taxes paid (net of refunds) | - | - |
| Net Cash Flow from Operating Activities(A) | 44.78 | 286.70 |
| B. CASH FLOW FROM INVESTING ACTIVITIES | | |
| Investments in Equity Instruments | 247.31 | 270.90 |
| Purchase / Sale of Fixed Assets | - | - |
| Increase/(decrease) in Long Term Loan & Advances | 997.66 | 46.40 |
| Net Cash Flow from Investing Activities(B) | 750.35 | 317.30 |
| C. CASH FLOW FROM FINANCING ACTIVITIES | | |
| Proceed (Repayment) from long term borrowing | - | - |
| Proceed (Repayment) from short term borrowing | - | - |
| Proceed from Preferential Warrants | 630.00 | - |
| Net Cash Flow from Financing Activities(C) | 630.00 | - |
| Net increase/(decrease) in cash & cash equivalents(A+B+C) | 165.13 | 30.60 |
| Cash and Cash equivalents (Opening Balance) | 201.63 | 1.69 |
| Cash and Cash equivalents (Closing Balance) | 36.50 | 32.29 |

Previous year figure have been regrouped/ reclassified wherever necessary

As per our report of even date
For, Rishi Sekhri and Associates,
Chartered Accountants
FRN: 128216w

SD/-
CA Rishi Sekhri
Partner
M.NO. 126656

Place: Mumbai
Date : 07th November, 2025

For and on Behalf of the Board
For, Biogen Pharmachem Industries Limited

Kelash Bunkar
Wholetime Director

Place: Rajkot
Date : 07th November, 2025



RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.
Tel.: 9820501848, Email : rishisekhri@gmail.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report To
The Board of Directors
Biogen Pharmachem Industries Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Biogen Pharmachem Industries Limited** (the "Company") for the quarter ended September 30, 2025 and year to date from April 01, 2025 to September 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Rishi Sekhri and Associates
Chartered Accountants
FRN: 128216W

CA Rishi Sekhri
Partner
NO. 126656

PLACE: Mumbai
Date: 07/11/2025
UDIN: 25126656NTKTCK6156

